Weekly Digest – April 2024 Weekly Digest – April 2024 10 Apr 2024: Merck’s $208m acquisition of Abceutics aims to enhance ADC safety Merck & Co. acquired UB’s spinout, Abceutics, for $208 million to enhance ADC safety The deal included […]
Weekly Digest – April 2024 Weekly Digest – April 2024 10 Apr 2024: TORL BioTherapeutics secures $158 million to advance its ADC oncology pipeline through Series B-2 financing TORL BioTherapeutics secures $158 million in Series B-2 financing led by Deep […]
Weekly Digest – April 2024 Weekly Digest – April 2024 9 Apr 2024: BioCity’s first-in-class ADC targeting Glypican 3 clears FDA’s IND application BioCity Biopharma gains FDA clearance for Phase 1 study of BC2027, a first-in-class ADC targeting Glypican 3 […]
Weekly Digest – April 2024 Weekly Digest – April 2024 8 Apr 2024: Genmab to acquire ADC maker ProfoundBio Genmab to acquire ProfoundBio for $1.8 billion Acquisition includes three clinical-stage drug candidates: Rinatabart sesutecan targets folate receptor α in ovarian […]
